Skip to main content

Advertisement

SpringerLink
Log in

The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant

  • Letter to the Editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Key TJ, Allen NE, Spencer EA, Travis RC (2002) The effect of diet on risk of cancer. Lancet 360:861–868

    Article  PubMed  CAS  Google Scholar 

  2. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360:573–587

    Article  PubMed  CAS  Google Scholar 

  3. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304:1684–1692

    Article  PubMed  CAS  Google Scholar 

  4. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Writing group for the Women’s Health Initiative investigators risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333

    Article  PubMed  CAS  Google Scholar 

  5. LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, Howard BV, Lewis CE, Wactawski-Wende J (2011) Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 305:1305–1314

    Article  PubMed  CAS  Google Scholar 

  6. Jordan VC, Ford LG (2011) Paradoxical clinical effect of estrogen on breast cancer risk: a “New” biology of estrogen-induced apoptosis. Cancer Prev Res 4:633–637

    Article  CAS  Google Scholar 

  7. Lewis-Wambi JS, Jordan VC (2009) Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res 11:206

    Article  PubMed  Google Scholar 

  8. Pasqualini JR (2007) Progestins and breast cancer. Gynecol Endocrinol 23(Suppl 1):32–41

    Article  PubMed  CAS  Google Scholar 

  9. Wiebe JP (2006) Progesterone metabolites in breast cancer. Endocr Relat Cancer 13:717–738

    Article  PubMed  CAS  Google Scholar 

  10. Cheng ZN, Shu Y, Liu ZQ, Wang LS, Ou-Yang DS, Zhou HH (2001) Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin 22:148–154

    PubMed  CAS  Google Scholar 

  11. Cribb AE, Knight MJ, Dryer D, Guernsey J, Hender K, Tesch M, Saleh TM (2006) Role of polymorphic human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol Biomark Prev 15:551–558

    Article  CAS  Google Scholar 

  12. Yamazaki H, Shimada T (1997) Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys 346:161–169

    Article  PubMed  CAS  Google Scholar 

  13. Wedlund PJ (2000) The CYP2C19 enzyme polymorphism. Pharmacology 61:174–183

    Article  PubMed  CAS  Google Scholar 

  14. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594–598

    PubMed  Google Scholar 

  15. Roddam PL, Rollinson S, Kane E, Roman E, Moorman A, Cartwright R, Morgan GJ (2000) Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia. Pharmacogenetics 10:605–615

    Article  PubMed  CAS  Google Scholar 

  16. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103–113

    Article  PubMed  CAS  Google Scholar 

  17. Justenhoven C, Hamann U, Pierl CB, Baisch C, Harth V, Rabstein S, Spickenheuer A, Pesch B, Bruning T, Winter S, Ko YD, Brauch H (2009) CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat 115:391–396

    Article  PubMed  CAS  Google Scholar 

  18. Justenhoven C, Pierl CB, Haas S, Fischer HP, Baisch C, Hamann U, Harth V, Pesch B, Bruning T, Vollmert C, Illig T, Dippon J, Ko YD, Brauch H (2008) The CYP1B1_1358_GG genotype is associated with estrogen receptor-negative breast cancer. Breast Cancer Res Treat 111:171–177

    Article  PubMed  CAS  Google Scholar 

  19. Pesch B, Ko Y, Brauch H, Hamann U, Harth V, Rabstein S, Pierl C, Fischer HP, Baisch C, Justenhoven C, Ranft U, Bruning T (2005) Factors modifying the association between hormone-replacement therapy and breast cancer risk. Eur J Epidemiol 20:699–711

    Article  PubMed  Google Scholar 

  20. Wedren S, Lovmar L, Humphreys K, Magnusson C, Melhus H, Syvanen AC, Kindmark A, Landegren U, Fermer ML, Stiger F, Persson I, Baron J, Weiderpass E (2004) Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study. Breast Cancer Res 6:R437–R449

    Article  PubMed  CAS  Google Scholar 

  21. Olson JE, Ma CX, Pelleymounter LL, Schaid DJ, Pankratz VS, Vierkant RA, Fredericksen ZS, Ingle JN, Wu Y, Couch F, Sellers TA, Weinshilboum RM, Vachon CM (2007) A comprehensive examination of CYP19 variation and breast density. Cancer Epidemiol Biomark Prev 16:623–625

    Article  CAS  Google Scholar 

  22. Giles GG, English DR (2002) The Melbourne Collaborative Cohort Study. IARC Sci Publ 156:69–70

    PubMed  CAS  Google Scholar 

  23. Schrauder M, Frank S, Strissel PL, Lux MP, Bani MR, Rauh C, Sieber CC, Heusinger K, Hartmann A, Schulz-Wendtland R, Strick R, Beckmann MW, Fasching PA (2008) Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer. J Cancer Res Clin Oncol 134:873–882

    Article  PubMed  CAS  Google Scholar 

  24. Key TJ (2011) Endogenous oestrogens and breast cancer risk in premenopausal and postmenopausal women. Steroids 76:812–815

    Article  PubMed  CAS  Google Scholar 

  25. Kurzawski M, Gawronska-Szklarz B, Wrzesniewska J, Siuda A, Starzynska T, Drozdzik M (2006) Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol 62:877–880

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study and the GENICA study was supported by the Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Institute of Pathology, Medical Faculty of the University of Bonn, Deutsches Krebsforschungszentrum, Heidelberg, and the Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, Germany. The SASBAC study was supported by the Märit and Hans Rausing’s Initiative Against Breast Cancer, the National Institutes of Health (RO1 CA58427), the Agency for Science, Technology and Research (A*STAR; Singapore), and the Swedish Research Council. J Li was a recipient of the A*STAR Graduate Scholarship. KH was supported by the Swedish Research Council (523-2006-972). MSC is a Senior Research Fellow of the Australian National Health and Medical Research Council and a Victorian Breast Cancer Research Consortium Group Leader. MCCS is supported by Cancer Council Victoria and by NHMRC (Grants 209057, 251533, 396414, 504711, 504715). The BBCC study was supported by the ELAN program of the University Hospital Erlangen. All authors disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations.

Author information

Authors and Affiliations

  1. Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany

    Christina Justenhoven, Ofure Obazee, Stefan Winter & Hiltrud Brauch

  2. University of Tübingen, Tübingen, Germany

    Christina Justenhoven, Ofure Obazee, Stefan Winter & Hiltrud Brauch

  3. Departments of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

    Fergus J. Couch & Janet E. Olson

  4. Health Sciences Research, Mayo Clinic, Rochester, MN, USA

    Fergus J. Couch & Janet E. Olson

  5. Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden

    Per Hall, Ulf Hannelius, Jingmei Li & Keith Humphreys

  6. Human Genetics, Genome Institute of Singapore, Singapore, Singapore

    Jingmei Li

  7. Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia

    Gianluca Severi, Graham Giles & Laura Baglietto

  8. Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Melbourne, Australia

    Gianluca Severi, Graham Giles & Laura Baglietto

  9. Genetic Epidemiology Laboratory, Depatment of Pathology, The University of Melbourne, Victoria, Australia

    Melissa Southey

  10. Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA

    Peter A. Fasching

  11. Department of Gynecology and Obstetrics, University Breast Center, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-Nuremberg, Erlangen, Erlangen, Germany

    Peter A. Fasching & Matthias W. Beckmann

  12. Institute of Human Genetics, Friedrich-Alexander University Erlangen Nuremberg, Erlangen, Germany

    Arif B. Ekici

  13. Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany

    Ute Hamann

  14. Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany

    Christian Baisch & Yon-Dschun Ko

  15. Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, Germany

    Volker Harth, Sylvia Rabstein, Anne Lotz, Beate Pesch & Thomas Brüning

Authors
  1. Christina Justenhoven
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ofure Obazee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefan Winter
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fergus J. Couch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Janet E. Olson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Per Hall
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ulf Hannelius
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jingmei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Keith Humphreys
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Gianluca Severi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Graham Giles
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Melissa Southey
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Laura Baglietto
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Peter A. Fasching
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Matthias W. Beckmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Arif B. Ekici
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Ute Hamann
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Christian Baisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Volker Harth
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Sylvia Rabstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Anne Lotz
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Beate Pesch
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Thomas Brüning
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Yon-Dschun Ko
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Hiltrud Brauch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christina Justenhoven.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Justenhoven, C., Obazee, O., Winter, S. et al. The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant. Breast Cancer Res Treat 131, 347–350 (2012). https://doi.org/10.1007/s10549-011-1827-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-011-1827-1

Keywords

Search

Navigation